Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that its management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that its management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. The conference runs from June 1-4, 2021, during which management will also engage in one-on-one meetings. Investors can access a live webcast and archived recording via the Phathom website, available for 90 days post-event. Phathom focuses on developing treatments for gastrointestinal diseases, with exclusive rights to vonoprazan for acid-related disorders.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was +1.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.
Company management will also participate in one-on-one meetings during the virtual conference which runs from June 1-4, 2021.
To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.
CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.